XML 34 R25.htm IDEA: XBRL DOCUMENT

Revenues (Tables)

3 Months Ended

Mar. 31, 2023

Revenue from Contract with Customer [Abstract]

Disaggregation of revenue by product and by geographic area

Revenues were as follows (in millions):


						Three months ended March 31,
						2023																		2022
						U.S.						ROW						Total						U.S.						ROW						Total
Prolia						$	623					$	304					$	927					$	582					$	270					$	852
ENBREL						564						15						579						843						19						862
XGEVA						384						152						536						368						134						502
Otezla						294						98						392						350						101						451
Repatha						197						191						388						165						164						329
Nplate						246						116						362						156						110						266
KYPROLIS						234						124						358						196						91						287
Aranesp						115						240						355						137						221						358
EVENITY						164						90						254						110						60						170
Other products(1)						1,154						541						1,695						1,130						524						1,654
Total product sales(2)						$	3,975					$	1,871					5,846						$	4,037					$	1,694					5,731
Other revenues																		259																		507
Total revenues																		$	6,105																	$	6,238

____________

(1) Consists of product sales of our non-principal products, as well as our Bergamo and Gensenta subsidiaries.

(2) Hedging gains and losses, which are included in product sales, were not material for the three months ended March 31, 2023 and 2022.